Last reviewed · How we verify
Prednisone (Cortancyl®)
Prednisone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties.
Prednisone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. Used for Rheumatoid arthritis, Multiple sclerosis, Asthma.
At a glance
| Generic name | Prednisone (Cortancyl®) |
|---|---|
| Also known as | experimental arm |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the production of inflammatory mediators and suppressing the immune system. This leads to a reduction in inflammation and swelling, which can help alleviate symptoms associated with various conditions.
Approved indications
- Rheumatoid arthritis
- Multiple sclerosis
- Asthma
- Allergic reactions
- Urticaria
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Weight gain
- Increased blood pressure
- Osteoporosis
- Glaucoma
- Cataracts
- Hypokalemia
Key clinical trials
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease (PHASE3)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone (Cortancyl®) CI brief — competitive landscape report
- Prednisone (Cortancyl®) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI